Vineet Bhatnagar

The Indian market has already registered a 10 percent rally so far in the year 2017 and about 15 percent from the December low of 7,900.

See Nifty range between 8600 and 9600-9800 in 3-6 months: PhillipCapital

In an interview to CNBC-TV18, Vineet Bhatnagar, MD of PhillipCapital said that there are several uncertainties over the government format.

PhilipCapital conclave to focus on future bottlenecks in agri

Speaking to CNBC-TV18, Vineet Bhatnagar, MD of the company said that the larger thrust will be on future bottlenecks for the agriculture industry. Seed, fertilizer as well as irrigation are likely to be the focus areas.

Nifty to test 8350 by June end; rural demand key: PhillipCapital

Optimism for the Indian equity markets prevails given Nifty has crossed and sustained 8250 level convincingly over the last few session, says Vineet Bhatnagar, MD, PhillipCapital. 

Buy Mindtree, Persistent, Firstsource: Vineet Bhatnagar

Vineet Bhatnagar, MD at PhillipCapital advises buying Mindtree, Persistent Systems and Firstsource Solutions.

Look at Mahindra CIE Automotive: Vineet Bhatnagar

Vineet Bhatnagar, MD at PhillipCapital is of the view that one may look at Mahindra CIE Automotive.

Mkts in risk-off mode; Nifty to hold 7500: PhillipCapital

Vineet Bhatnagar of PhillipCapital says investors should use the current market weakness to buy stocks.

7800-8000 bottom to throw sharp relief rallies: Phillip Cap

India will be at the forefront when a rebound happens, says Vineet Bhatnagar of Phillip Capital. He advises staying with safe havens IT and pharma stocks.

Bank of Baroda valuation pick, says Vineet Bhatnagar

Vineet Bhatnagar, MD at Phillip Capital is of the view that Bank of Baroda is a valuation pick.

Keep BOI, PNB, SBI in portfolio: Vineet Bhatnagar

Vineet Bhatnagar - MD at Phillip Capital is of the view that one may keep Bank of India, Punjab National Bank and State Bank of India in the portfolio.

See 10-15% upside in midcap pharma space: Vineet Bhatnagar

Vineet Bhatnagar - MD at Phillip Capital expects 10-15 percent upside in midcap pharma stocks including Glenmark Pharma, Divis Laboratories, Torrent Pharma and Cadila Healthcare.

Nifty may not hit 9K in a hurry; like Glenmark: PhillipCap

Going ahead, Vineet Bhatnagar, managing director, Phillip Capital expects refinery, oil marketing companies and ONGC to show strong upward moves. He also sees another 10-15 percent upside in Glenmark, Torrent Pharma and Divis Lab.

Super run but fundamentals still shaky, don't buy: Experts

Experts watching Tuesday's sudden rally say only pockets of market has caught the momentum which makes it difficult to take a call on the Nifty.

Here's why market may not immediately resume its bull run

Nirmal Jain, Chairman of IIFL does not see Nifty breaching 7,950 - 8,000 levels, as investors are looking at every correction as an opportunity to buy.

Tech Mahindra top pick, says Vineet Bhatnagar

According to Vineet Bhatnagar, MD at PhillipCapital, Tech Mahindra is a top pick.

Pick Maruti Suzuki, UltraTech Cement: Vineet Bhatnagar

According to Vineet Bhatnagar, MD at PhillipCapital, one may pick Maruti Suzuki, UltraTech Cement and Emami.

Correction likely, but Nifty may hold 8460: Phillip Capital

Bhatnagar is bullish on banking stocks like Lakshmi Vilas, Federal Bank and City Union in the short term

Prefer Tata Steel, L&T: Vineet Bhatnagar

Vineet Bhatnagar, Managing Director at Phillipcapital is of the view that one may pick Tata Steel from the metal space.

Vineet Bhatnagar positive on NBFC space

Vineet Bhatnagar, Managing Director at Phillipcapital has a positive view on NBFC space.

NCC top pick, says Vineet Bhatnagar

Vineet Bhatnagar, Managing Director at Phillipcapital is of the view that NCC is the top pick from the construction space.

'FIIs buying index futures; banks to do well in Nov series'

Vineet Bhatnagar, MD, PhillipCapital sees immediate resistance for the Nifty at 8180.

Avoid real estate, infra, power space: Vineet Bhatnagar

Vineet Bhatnagar, managing director of Phillip Capital is of the view that one may avoid real estate, infrastructure and power space.

Interact with CNBC-TV18: Vineet Bhatnagar sees Nifty between 5970-6300 in Feb series

Vineet Bhatnagar, MD, PhillipCap says the expected trading range for February series is between 5970 and 6300 level, which is very wide.

Jan series may end at 6100; Bank Nifty to suffer: Expert

Vineet Bhatnagar, MD, PhillipCapital says the market may see some intraday recovery.

See Nifty above 6300; upbeat on Tata Steel, L&T: PhillipCap

Vineet Bhatnagar, MD, PhillipCapital is of the view that Bank Nifty could also make higher highs given the fact that the broad based index is expected to move higher.